First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.
<h4>Objectives</h4>This study aims to evaluate the cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) from the perspective of U.S. healthcare payers.<h4>Methods</...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0325808 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <h4>Objectives</h4>This study aims to evaluate the cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) from the perspective of U.S. healthcare payers.<h4>Methods</h4>A 10-year partitioned survival model was developed using survival data from the JUPITER-06 clinical trial (NCT03829969). Costs included only direct medical expenses, and health utility values were derived from published literature. One-way and probabilistic sensitivity analysis were performed to assess the robustness of the model.<h4>Results</h4>Toripalimab combined with chemotherapy incurred an incremental cost of $64,483.3 and achieved an incremental effectiveness of 0.53 quality-adjusted life-years (QALY) compared to chemotherapy alone, resulting in an incremental cost-effectiveness ratio (ICER) of $122,771.67 per QALY. This ICER is below the willingness-to-pay threshold in the United States ($150,000). The model results were sensitive to the cost of toripalimab and the utility values of both progression-free and progressed disease states.<h4>Conclusions</h4>The findings indicate that toripalimab combined with chemotherapy as a first-line treatment for advanced ESCC in the United States provides a cost-effective benefit in comparison to chemotherapy alone. |
|---|---|
| ISSN: | 1932-6203 |